Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

References

• SunCCBodurkaDCWeaverCBRankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancerSupport Care Cancer200513421922715538640
   PubMed Web of Science ®Google Scholar
• KrisMGWhy do we need another antiemetic? Just askJ Clin Oncol200321224077408014559888
   PubMed Web of Science ®Google Scholar
• BallatoriERoilaFRuggeriBThe impact of chemotherapy-induced nausea and vomiting on health-related quality of lifeSupport Care Cancer200715217918516941136
   PubMed Web of Science ®Google Scholar
• GlausAKnippingCMorantRChemotherapy-induced nausea and vomiting in routine practice: a European perspectiveSupport Care Cancer2004121070871515278682
   PubMed Web of Science ®Google Scholar
• CohenLde MoorCAEisenbergPMingEEHuHChemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settingsSupport Care Cancer200715549750317103197
   PubMed Web of Science ®Google Scholar
• BurkeTAWisniewskiTErnstFRResource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital settingSupport Care Cancer201119113114020101417
   PubMed Web of Science ®Google Scholar
• Ihbe-HeffingerAEhlkenBBernardRThe impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization, and costs in German cancer centersAnn Oncol200415352653614998860
   PubMed Web of Science ®Google Scholar
• TinaShih YCXuYEltingLSCosts of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapyCancer2007110367868517567835
   PubMed Web of Science ®Google Scholar
• MorrowGRRoscoeJAHickokJTInitial control of chemotherapy-induced nausea and vomiting in patient quality of lifeOncology (Williston Park)1998123 Suppl 432379556781
   PubMed Web of Science ®Google Scholar
• HeskethPJChemotherapy-induced nausea and vomitingN Engl J Med2008358232482249418525044
   PubMed Web of Science ®Google Scholar
• WarrDGGrunbergSMGrallaRJThe oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomized, double-blind, placebo controlled trialsEur J Cancer20054191278128515939263
   PubMed Web of Science ®Google Scholar
• PetoRDaviesCGodwinJComparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trialsLancet2012379981443244422152853
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE)Early and locally advanced breast cancer: diagnosis and treatment. Full guideline (CG80)22009 [updated May 30, 2012]. Available from: http://www.nice.org.uk/CG0FullGuidelineAccessed Jun 2012
   Google Scholar
• GrunbergSMOsobaDHeskethPJEvaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an updateSupport Care Cancer2005132808415599601
   PubMed Web of Science ®Google Scholar
• RoilaFHerrstedtJAaproMGuideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnn Oncol201021Suppl 5v232v24320555089
   PubMed Web of Science ®Google Scholar
• University College Hospital NHS Foundation TrustAntiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy2010 Available from: http://www.medicinesresources.nhs.uk/upload/documents/Communities/London_CNDG/Antiemetic_guidelines_November_2010.pdfAccessed Jun 2012
   Google Scholar
• BaschEPrestrudAAHeskethPJAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201129314189419821947834
   PubMed Web of Science ®Google Scholar
• HeskethPJGrunbergSMGrallaRJThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, doubleblind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study GroupJ Clin Oncol200321224112411914559886
   PubMed Web of Science ®Google Scholar
• Poli-BigelliSRodrigues-PereiraJCaridesADAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin AmericaCancer200397123090309812784346
   PubMed Web of Science ®Google Scholar
• de WitRHerrstedtJRapoportBThe oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase 3 clinical trialsEur J Cancer200440340341014746859
   PubMed Web of Science ®Google Scholar
• WarrDGHeskethPJGrallaRJEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyJ Clin Oncol200523122822283015837996
   PubMed Web of Science ®Google Scholar
• HerrstedtJMussHBWarrDGEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyCancer200510471548155516104039
   PubMed Web of Science ®Google Scholar
• RapoportBLJordanKBoiceJAAprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind studySupport Care Cancer201018423431
   Web of Science ®Google Scholar
• Personal Social Services Research UnitUnit Costs of Health and Social Care 2010 Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2010/index.phpAccessed Jun 2012
   Google Scholar
• Department of HealthNHS Reference Costs for 2009–2010Appendix NSRC04: NHS trust and PCT combined reference cost schedules2011 Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2009-2010Accessed Jun 2012
   Google Scholar
• Monthly Index of Medical Specialities. [database on the Internet]LondonHaymarket Medical Media2011 Available from: http://www.mims.co.uk/go/mims_monthlyAccessed Jun 2012
   Google Scholar
• Joint Formulary CommitteeBritish National Formulary61 ednBritish Medical Association and the Royal Pharmaceutical Society of Great BritainLondon, UK32011
   Google Scholar
• NHS Business Services Authority, NHS Prescription Services (compiled on behalf of the Department of Health)Drug Tariff52011 NorwichTSO2011
   Google Scholar
• GrunbergSMBoutinNIrelandAMinerSSilveiraJAshikagaTImpact of nausea/vomiting on quality of life as a visual analogue scale-derived utility scoreSupport Care Cancer1996464354398961474
   PubMed Web of Science ®Google Scholar
• BörjesonSHurstiTJPetersonCSimilarities and differences in assessing nausea on a verbal category scale and a visual analogue scaleCancer Nurs19972042602669265812
   PubMed Web of Science ®Google Scholar
• SunCCBodurkaDCDonatoMLPatient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?Gynecol Oncol200287111812812468352
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE)Guide to the methods of technology appraisal62008 Available from: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdfAccessed Jun 2012
   Google Scholar
• National Chemotherapy Advisory GroupChemotherapy Services in England: Ensuring quality and safetyUK Department of Health2009 Available from: http://webarchive.nationalarchives.gov.uk/20130107105354. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_104501.pdfAccessed Jun 2012
   Google Scholar
• AaproMMolassiotisADicatoMThe effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)Ann Oncol20122381986199222396444
   PubMed Web of Science ®Google Scholar
• KrisMGHeskethPJSomerfieldMRAmerican Society of Clinical Oncology guideline for antiemetics in oncology: update 2006J Clin Oncol200624182932294716717289
   PubMed Web of Science ®Google Scholar
• LatreilleJPaterJJohnstonDUse of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol1998163117411789508205
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic ResearchPrevention of cisplatin-induced delayed emesis: still unsatisfactorySupport Care Cancer20008322923210789965
   PubMed Web of Science ®Google Scholar
• GridelliCIannielloGAmbrosiniGA multicenter, double-blind, randomized trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesisInt J Oncol199710239540021533390
   PubMed Web of Science ®Google Scholar
• AnnemansLStrensDLoxEPetitCMalonneHCost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in BelgiumSupport Care Cancer200816890591517965891
   PubMed Web of Science ®Google Scholar